Close Menu
SUBSCRIBE
A

Anakinra

Comprehensive Guide to Anakinra: Uses, Dosage, Side Effects, and More

What is Anakinra?

Anakinra is a biologic response modifier used to treat rheumatoid arthritis (RA), neonatal-onset multisystem inflammatory disease (NOMID), and other autoinflammatory conditions. As a recombinant interleukin-1 (IL-1) receptor antagonist, this drug blocks IL-1 activity, reducing inflammation. Marketed under the brand name Kineret, the biologic is administered via subcutaneous injection. Anakinra’s benefits include its effectiveness in managing severe inflammatory diseases, but it requires monitoring for infection risk and injection-site reactions.

Overview of Anakinra

Generic Name: Anakinra

Brand Name: Kineret

Drug Group: Biologic response modifier; interleukin-1 receptor antagonist

The medication is used to:

  • Treat moderate to severe rheumatoid arthritis in adults, often with methotrexate.
  • Manage neonatal-onset multisystem inflammatory disease (NOMID) in children and adults.
  • Treat other autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes).
  • Off-label uses include Still’s disease or gout under specialist guidance.

Key Characteristics

Form: Prefilled syringes for subcutaneous injection (100 mg/0.67 mL).

Mechanism: Inhibits IL-1 signaling by competitively binding to IL-1 receptors.

Approval: FDA-approved (2001 for Kineret) and EMA-approved for RA and NOMID.

Kineret (anakinra) 100 mg injection box with prefilled syringe for subcutaneous use
A box of Kineret (anakinra) 100 mg prefilled syringes, an injectable medication used to treat rheumatoid arthritis and other inflammatory conditions.

Indications and Uses of Anakinra

Anakinra is indicated for:

Rheumatoid Arthritis: Reduces signs and symptoms in adults with moderate to severe RA, often as an adjunct to methotrexate.

Neonatal-Onset Multisystem Inflammatory Disease (NOMID): Controls inflammation and symptoms in children and adults.

Cryopyrin-Associated Periodic Syndromes (CAPS): Manages familial cold autoinflammatory syndrome and Muckle-Wells syndrome.

Off-Label Uses: Treats adult-onset Still’s disease, gout flares, or other IL-1-driven conditions under specialist supervision.

Note: The drug is used in patients with inadequate response to other therapies (e.g., DMARDs for RA) and requires careful infection screening.

Dosage of Anakinra

Important Note: Anakinra dosage must be prescribed by a healthcare provider. Dosing is weight-based for some indications and requires regular monitoring.

Dosage for Adults

Rheumatoid Arthritis:

  • 100 mg daily via subcutaneous injection.
  • Adjust or discontinue if no response after 3 months.

Neonatal-Onset Multisystem Inflammatory Disease (NOMID): 1–2 mg/kg daily (maximum 100 mg/day), adjusted per response and tolerance.

Dosage for Children

NOMID: 1–2 mg/kg daily (maximum 100 mg/day), titrated based on weight and inflammation markers.

Other CAPS: Similar dosing (1–2 mg/kg/day), under specialist supervision.

Dosage for Pregnant Women

Pregnancy Category B: Limited data; use only if benefits outweigh risks. Consult a rheumatologist or obstetrician.

Dosage Adjustments

Renal Impairment:

  • CrCl <30 mL/min: 100 mg every other day.
  • Severe impairment (CrCl <15 mL/min): Not recommended.

Hepatic Impairment: No specific adjustments; monitor for side effects.

Elderly: No specific adjustments; monitor for infections.

Additional Considerations

  • Administer at the same time daily, rotating injection sites to avoid irritation.
  • Refrigerate prefilled syringes; allow to reach room temperature before use.

How to Use Anakinra

Administration:

  • Subcutaneous Injection: Inject into the abdomen, thigh, or upper arm using a prefilled syringe; rotate sites.
  • Preparation: Let syringe reach room temperature (30 minutes) before use; do not shake.

Timing: Inject once daily, preferably at the same time.

Monitoring: Watch for injection-site reactions or signs of infection.

Additional Tips:

  • Avoid active infections before starting; report fever or chills immediately.
  • Follow proper syringe disposal guidelines (e.g., sharps container).

Contraindications for Anakinra

The biologic is contraindicated in:

  • Patients with hypersensitivity to Anakinra, Escherichia coli-derived proteins, or components.
  • Patients with active, severe infections (e.g., sepsis, tuberculosis).

Warnings & Precautions

General Warnings

Infection Risk: Increased susceptibility to bacterial, viral, or fungal infections; screen for latent TB before starting.

Injection-Site Reactions: Common (e.g., redness, swelling); may require dose adjustment or discontinuation.

Neutropenia: Risk of low white blood cell count; monitor regularly.

Hypersensitivity: Rare anaphylaxis or severe allergic reactions; discontinue if occurs.

Malignancy: Long-term use may increase cancer risk; monitor closely.

Use in Specific Populations

Pregnancy: Category B; limited data; use cautiously with specialist consultation.

Breastfeeding: Excreted in breast milk; weigh benefits versus risks.

Elderly: Increased infection risk; monitor closely.

Children: Approved for NOMID and CAPS; monitor for growth or development effects.

Renal Impairment: Adjust dose in severe cases; avoid in end-stage renal disease.

Additional Precautions

  • Inform your doctor about recent infections, immune disorders, or vaccination history before starting the medication.
  • Avoid live vaccines during treatment.

Overdose and Management of Anakinra

Overdose Symptoms

  • Severe injection-site reactions or allergic responses.
  • Increased infection risk or neutropenia.
  • Fatigue or malaise.

Immediate Actions

Contact Emergency Services: Seek medical help if overdose is suspected.

Supportive Care: Monitor for infections or allergic reactions; provide supportive treatment.

Monitor: Check white blood cell count and renal function.

Additional Notes

  • Overdose is rare with proper dosing; use only as prescribed.
  • Report persistent symptoms promptly.

Side Effects of Anakinra

Common Side Effects

  • Injection-site reaction (e.g., redness, 50–70%)
  • Headache (10–15%)
  • Nausea (5–10%)
  • Fatigue (3–5%)

These effects are often mild and may decrease over time.

Serious Side Effects

Infections: Fever, chills, or persistent cough.

Allergic Reactions: Rash, swelling, or difficulty breathing.

Hematologic: Unusual bruising or bleeding (neutropenia).

Neurological: Severe headache or confusion (rare).

Additional Notes

  • Regular monitoring for infections and blood counts is essential.
  • Report any unusual symptoms immediately.

Drug Interactions with Anakinra

The medication may interact with:

TNF Inhibitors (e.g., Etanercept): Increased infection risk; avoid concurrent use.

Immunosuppressants (e.g., Azathioprine): Enhance immunosuppression; monitor closely.

Live Vaccines: Reduced efficacy and increased infection risk; avoid during treatment.

Other Biologics: Potential for additive immunosuppression; consult a specialist.

Action: Provide your healthcare provider with a complete list of medications and supplements.

Patient Education or Lifestyle

Medication Adherence: Inject Anakinra daily as prescribed to ensure efficacy. Refill prescriptions early.

Monitoring: Report signs of infection (e.g., fever) or injection-site issues immediately. Regular blood tests are needed.

Lifestyle: Maintain good hygiene to reduce infection risk; avoid contact with sick individuals.

Diet: Stay hydrated and maintain a balanced diet; no specific restrictions.

Emergency Awareness: Know signs of severe infection or allergic reactions; seek immediate care if present.

Vaccination: Get non-live vaccines before starting; consult your doctor about timing.

Pharmacokinetics

Absorption: Well-absorbed subcutaneously; peak plasma concentration at 3–7 hours.

Distribution: Volume of distribution ~0.2–0.3 L/kg; limited central nervous system penetration.

Metabolism: Not metabolized; cleared via kidneys.

Excretion: Primarily renal (>90% unchanged).

Half-Life: 4–6 hours.

Pharmacodynamics

The biologic exerts its effects by:

  • Blocking IL-1 receptor signaling, reducing inflammation in RA and NOMID.
  • Inhibiting pro-inflammatory cytokine release in autoinflammatory diseases.
  • Demonstrating rapid onset (within days) for symptom relief in acute flares.
  • Effective when combined with other therapies for chronic conditions.

Storage

Temperature: Store at 2–8°C (36–46°F); do not freeze.

Protection: Keep in original carton to protect from light; avoid shaking.

Safety: Store out of reach of children; use within 30 days if not refrigerated.

Disposal: Dispose of used syringes in a sharps container per local regulations.

Frequently Asked Questions (FAQs)

Q: What does Anakinra treat?
A: The drug treats rheumatoid arthritis and neonatal-onset inflammatory disease.

Q: Can Anakinra cause infections?
A: Yes, infection risk is increased; report fever or chills immediately.

Q: Is Anakinra safe for children?
A: Approved for NOMID and CAPS in children; monitor for side effects.

Q: How is Anakinra administered?
A: Via subcutaneous injection once daily.

Q: How long is Anakinra treatment?
A: Ongoing for chronic conditions; reassess every 3–6 months.

Regulatory Information

The medication is approved by:

  • U.S. Food and Drug Administration (FDA): Approved in 2001 (Kineret) for RA; later for NOMID.
  • European Medicines Agency (EMA): Approved for RA and CAPS.
  • Other Agencies: Approved globally for equivalent uses; consult local guidelines.

References

  1. U.S. Food and Drug Administration (FDA). (2023). Kineret (Anakinra) Prescribing Information.
    • Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
  2. European Medicines Agency (EMA). (2023). Anakinra Summary of Product Characteristics.
    • EMA’s comprehensive information on the medication’s indications and precautions in Europe.
  3. National Institutes of Health (NIH). (2023). Anakinra: MedlinePlus Drug Information.
    • NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
  4. World Health Organization (WHO). (2023). WHO Model List of Essential Medicines: Anakinra.
    • WHO’s inclusion of Anakinra for autoinflammatory diseases.
  5. Arthritis & Rheumatology. (2020). Anakinra in Rheumatoid Arthritis and NOMID.
    • Peer-reviewed article on Anakinra efficacy (note: access may require a subscription).
Disclaimer: This article provides general information about Anakinra for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider, such as a rheumatologist or immunologist, before using this drug or making any medical decisions. Improper use of this medication can lead to serious health risks, including infections or allergic reactions.

 

Dr. Andrew Parker is a board-certified internal medicine physician with over 10 years of clinical experience. He earned his medical degree from the University of California, San Francisco (UCSF), and has worked at leading hospitals including St. Mary’s Medical Center. Dr. Parker specializes in patient education and digital health communication. He now focuses on creating clear, accessible, and evidence-based medical content for the public.

Related Posts